The phrase "assay version" is correct and usable in written English.
It can be used in contexts related to scientific testing or analysis, particularly in reference to a specific iteration or format of an assay.
Example: "The laboratory has developed a new assay version that improves the accuracy of the results."
Alternatives: "test version" or "analysis version".
Objective: The aim of this study was to evaluate the LiPA HIV-1 RT assay version 1 for monitoring drug resistance mutations in comparison to full-length sequencing.
Results: Amongst the 555 individuals tested, 438 (60.7%) had detectable (>500 copies/ml) HIV RNA (bDNA assay, version 2) at baseline.
Study design: Two hundred and forty-four samples were analyzed using the LiPA HIV-1 RT assay version 1 and were compared with full RT gene sequences obtained by in-house sequencing.
The LiPA HIV-1 RT assay version 1 gives a high degree of samples with at least one missing signal (39.4%) in our cohort and this is not acceptable for a diagnostic tool.
HIV-1 viral load was quantified in plasma by the Amplicor HIV-1 Monitor assay, version 1.5 (Roche).
Complementary DNA was amplified, and labeled according to the Affymetrix two-cycle GeneChip® Eukaryotic small sample target labeling assay (version II).
To study the skeletal troponin I (skTnI) cross-reactivity of four different commercially available antibodies in four cardiac troponin I (cTnI) research assay versions having the same epitope specificity as evidenced by peptide mapping.
HIV RNA was measured in cell-free CSF and plasma by the Roche Amplicor Monitor assay (versions 1.0 and 1.5, Roche Diagnostic Systems, Inc., Branchburg, N.J) using the standard and Ultrasensitive extraction methods.
HIV RNA was measured in cell-free CSF and plasma using the ultrasensitive Amplicor HIV Monitor assay (versions 1.0 and 1.5; Roche Molecular Diagnostic Systems, Branchburg, NJ) performed in the UCSF Virology Research Core Laboratory.
Acceptable assays were modified versions of the ultrasensitive Amplicor assay [ 4, 22] (if the lower limit of detection was recorded and below 50 copies/ml), the Abbott RealTime assay, and the Roche TaqMan assay versions 1 and 2. These last three assays have lower limits of detection of 40, 40 and 20 copies/ml respectively [ 6].
The Human miScript Primer Assays version 9.0 and 11.0 from Qiagen, designed to detect 804 human miRNA probes, were used according to the manufacturer's guidelines.
